STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3796 by analyst upside · 2026-09-10
JNJ
Johnson & Johnson
Healthcare · Market Cap $644B · P/E 31.2x
ANALYST PRICE TARGET
+3.2%
implied upside to consensus target
Current Price $267.08
Consensus Target $275.64
Bull Target $320.0
Bear Target $190.0
Analysts Covering 22
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
11
Hold
6
Sell
0
52-Week Low $173.33
52-Week High $281.07
YTD Return +30.9%
FUNDAMENTALS
Market Cap $644B
P/E Ratio (TTM) 31.2x
Forward P/E 21.7x
EPS (TTM) $8.55
PEG Ratio 4.38
Dividend Yield 1.99%
Revenue (TTM) $97.9B
Profit Margin 21.5%
52-WEEK RANGE
52-Week Low $173.33
52-Week High $281.07
Current Price $267.08
Bear Target $190.0
Bull Target $320.0
● Now $267.08 ● Target $275.64
TRADING DATA
Avg Volume 7.8M
YTD Return +30.9%
Analyst Count 22
Consensus Buy
Upside to Target +3.2%
Last Updated 2026-09-10

ANALYST SUMMARY

Johnson & Johnson (JNJ) is currently trading at $267.08 with a Wall Street consensus price target of $275.64, implying potential upside of 3.2% over the next 12 months. 22 analysts currently cover JNJ, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $320.0, while the most cautious has a target of $190.0.

JNJ operates in the Healthcare sector with a market capitalisation of $644B. The stock is up 30.9% year-to-date and is currently trading near the upper end of its 52-week range of $173.33 – $281.07.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for JNJ, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Buy → Buy 2026-09-02 33% win rate (6 calls)
Guggenheim - Reiterated
Buy → Buy 2026-08-06 62% win rate (8 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-08-03 Building track record
Guggenheim reit
Buy → Buy 2026-07-17 62% win rate (8 calls)
Raymond James - Reiterated
Outperform → Outperform 2026-07-16 Building track record
RBC Capital reit
Outperform → Outperform 2026-07-16 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-07-16 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-07-16 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
58
out of 100
Coverage depth
24/30
Consensus clarity
20/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →